Showing 2637 results
- Key Release /Der Nettoumsatz der fortzuführenden Geschäftsbereiche1 steigt 2019 um 9% (kWk2, +6% USD): Die Geschäftseinheit Pharmaceuticals wächst um 12% (kWk), getragen von Cosentyx (USD 3,6 …
- Media Release /With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in…
- Key Release /Q1 2020 net sales from continuing operations1 grew 13% (cc2, +11% USD) with double digit growth (cc) in Innovative Medicines and Sandoz: Key growth drivers include Entresto USD 569…
- Key Release /Der Nettoumsatz der fortzuführenden Geschäftsbereiche1 steigt im ersten Quartal 2020 um 13% (kWk2, +11% USD) mit zweistelligen Zuwächsen (kWk) bei Innovative Medicines und Sandoz: Zu den…
- Key Release /Au 1er trimestre 2020, chiffre d’affaires net des activités poursuivies1 en hausse de 13% (tcc2, +11% USD) avec une croissance à deux chiffres (tcc) d’Innovative Medicines et de Sandoz: Les…
- Media Release /Data from Phase III REACH2 study, published in The New England Journal of Medicine, demonstrate Jakavi can improve outcomes for patients with acute graft-versus-host disease (GvHD) who do not respond…
- Media Release /If approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah, joining approvals in children and young adults with r/r ALL, and adults…
- Media Release /New long-term data from EXPAND show patients with SPMS continuously treated with Mayzent® (siponimod) experienced lower risk of disability progression and cognitive decline than patients who delayed…
- Media Release /Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease Trial…
- Media Release /Technology has potential to reimagine treatment for amblyopia (“lazy eye”), a leading cause of vision loss in children and young adults1Acquisition expands the Novartis refractive disorder pipeline…
Pagination
- ‹ Previous page
- 1
- …
- 215
- 216
- 217
- 218
- 219
- 220
- 221
- …
- 264
- › Next page